Buoyancy based bioseparations

摘要 存在对用于稀有金属的高纯度分离的成本有效的技术的未满足的需求。 循环肿瘤细胞（CTC）。理想的隔离技术应该能够 符合以下标准：（a）最短处理时间;（B）最终样品体积低;（c） 从大血容量中分离;（d）白细胞和血液的低残留 组分;（e）高细胞活力;（f）与下游工艺的相容性， 聚合酶链反应或组织培养;（g）费用低，便于初级人员操作。 虽然有许多方法用于CTC分离，但没有一种方法将它们结合在一起 简单、低成本、效率和速度。以前，我们开发了一种新颖的方法， 漂浮微泡辅助从血液和血沉棕黄层中分离罕见肿瘤细胞。 MB有效（>80%回收率）和快速（少于20分钟）分离罕见肿瘤细胞 7毫升血液或22毫升血沉棕黄层。在第一阶段，Diagnologix，LLC与 加州圣地亚哥大学，以开发和测试一个原型的 直观且用户友好分离/收获装置与MB组合将 用于从复杂的生物流体中收获罕见的肿瘤细胞（例如，血液）。的 建议的设置将使容易清洗，免疫染色，遗传分析或培养 分离的CTC。MB方法与 磁珠将是高速，样品纯度，简单，灵活，最小的最终 样品量大、成本低。技术的价值主张在于定性 生物医学和临床应用中CTC分离和分析的定量改进 研究和潜在的临床诊断。

Abstract There is an unmet need for cost-efficient technologies for high purity isolation of rare circulating tumor cells (CTCs) from blood. An ideal isolation technique should be able to meet the following criteria: (a) minimal processing time; (b) low final sample volume; (c) isolation from large blood volume; (d) low carryover of leukocytes and blood components; (e) high cell viability; (f) compatibility with downstream processes such as PCR or tissue culturing; (g) low cost and ease of operation by entry-level personnel. While there are numerous approaches for CTC isolation, none of them combines simplicity, low cost, efficiency and speed. Previously, we developed a novel process of buoyant microbubble-assisted isolation of rare tumor cells from blood and buffy coats. MBs efficiently (>80% recovery) and fast (less than 20 min) isolated rare tumor cells from 7 ml blood or 22 ml buffy coats. For Phase I, Diagnologix, LLC has partnered with the University of California San Diego in order to develop and test a prototype of an intuitive and user-friendly separation/harvesting device that in combination with MBs will be used for harvesting rare tumor cells from complex biological fluids (e.g., blood). The proposed setup will enable easy washing, immunostaining, genetic analysis or culturing of isolated CTCs. The most important competitive advantages of MB approach vs. magnetic beads would be high speed, sample purity, simplicity, flexibility, minimal final sample volume and low cost. The value proposition of the technology is in the qualitative and quantitative improvement in CTC isolation and analysis for biomedical and clinical research and potentially for clinical diagnostics.